References
- Kim GE. Targeted therapies and radiation for the treatment of head and neck cancer. J Korean Soc Ther Radiol Oncol 2004;22;70-90
- Park HS, Lee NS. Molecular targeted therapy in cancer. J Kor Med Assoc 2003;I47:542-548
- David R, Barb H, Paul A, et al. Targeted therapies for nonsmall-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 2004;59:27-38 https://doi.org/10.1016/j.ijrobp.2004.01.054
- Herbert RS, Maddox AM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-3824 https://doi.org/10.1200/JCO.2002.03.038
- Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279 https://doi.org/10.1200/JCO.2001.19.13.3267
- Baselag J, Reschin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302 https://doi.org/10.1200/JCO.2002.03.100
- Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepideral growth factor monoclonal antibody EMD 7200 in patients with advanced solid tumors that express the epidermal growth factor. J Clin Oncol 2004;22:175-184 https://doi.org/10.1200/JCO.2004.05.114
- Matar P, Rojo R, Guzman M. Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and monoclonal antibody (IMC-C225) Evidence of synergy. Proc AACR 2003;44:918
- Cataldo B, Roberto B, Giampaolo T, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase. Clin Cancer Res 2000;6:4343-4350
- Giralt P.M, Harari K, Ang N, et al. A phase III study of high dose radiotherapy with or without cetuximab in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Radiat Oncol 2004;73(Suppl 1):217
- Baselga J, Herbst R, Lorusso P, et al. Continuous administration of ZD 1839 (Iressa), a novel oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability (Abst.686). Proc Am Soc Clin Oncol 2000;19:177a
- Herbst RS, Maddox AM, Rothenberg ML, et al. Selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in nonsmall-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-3825 https://doi.org/10.1200/JCO.2002.03.038
- Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594 https://doi.org/10.1172/JCI9621
- Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochemi 2000;69:145-182 https://doi.org/10.1146/annurev.biochem.69.1.145
- Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916 https://doi.org/10.1038/sj.onc.1203286
- Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 1998;4:763-771
- Pyo H, Choy H, Amorino GP, et al. Selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005
- Weimin L, Yuhchyau C, Wei W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003;26:100-103 https://doi.org/10.1097/00000421-200308000-00031
- Nazanin A, Lynn H, Melanie S, et al. NS 398 radiosensitizes and HNSCC cell line by possibly inhibiting radiationinduced expression of COX-2. Int J Radiat Oncol Biol Phys 2003;5:1405-1412
- Kaplan EL, Meir P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481 https://doi.org/10.2307/2281868
- Raben D, Bianco C, Milas L, et al. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol 2004;14:139-152 https://doi.org/10.1053/j.semradonc.2003.12.009
- Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-1140 https://doi.org/10.1016/S0959-8049(02)00013-8
- Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, et al. Combined targeted inhibition of bcl-2, bcl-xL, epidermal growth factor receptor, and protein kinase a type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin Cancer Res 2003;9:866-871
- Huang SM, Jonathan M, Bock M, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-1940
- Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-2707
- Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damaged repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174
- Eiko NM, Kathryn A, Mason M, et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 2004;58:369-375 https://doi.org/10.1016/j.ijrobp.2003.09.061
- Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non small lung cancer. J Clin Oncol 2003;21:2645-2650 https://doi.org/10.1200/JCO.2003.07.127
- Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002:;62:4307-4315
- Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science (Wash. DC) 1995;267:1782-788 https://doi.org/10.1126/science.7892601
- Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1:507-514
- Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-1292 https://doi.org/10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X
- Jeong SJ, Jeong MH, Jang JY, et al. Regulatory mechanism of radiation induced cancer cell death by the change of cell cycle. J Korean Soc Ther Radiol Oncol 2003;21:306-314
- Agarwal ML, Agarwal M, Taylor WR, Stark GR. P53 control both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblast. Proc Natl Acad Sci USA 1995;92:8493-8497 https://doi.org/10.1073/pnas.92.18.8493
- Grandis J, Tweardy D. Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-3584
- Kim KY, Seol JY, Jeon GA, Nam MJ. The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Cancer Letters 2003;183:157-166 https://doi.org/10.1016/S0304-3835(02)00519-0
- Lee HS, Choi YM, Kwon JC, et al. A novel chenodeoxycholic derivative HS-1200 enhances radiation-induced apoptosis in human MCF-7 breast cancer cells. J Korean Soc Ther Radiol Oncol 2004;22:145-154
- Jieying X, Jun C, Garry C, et al. Antisense BAG-1 sensitizes HeLa cells to apoptosis by multiple pathways. BBRC 2003;312:585-591
- Denis S, Armine V, Olga Yu, et al. 'Wages of fear': transient threefold decrease in intracellular ATP level impose apoptosis. Biochem Biophysic Acta 2004;1658:141-147 https://doi.org/10.1016/j.bbabio.2004.05.007